Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2
RW Joseph, JE Eckel-Passow, R Sharma… - Journal of …, 2012 - journals.lww.com
Ipilimumab improves overall survival (OS) in patients with metastatic melanoma including
those previously treated with high-dose interleukin-2 (HD IL-2). The primary objective of this
study was to determine if clinical response or progression-free survival (PFS) to HD IL-2
could predict benefit to subsequent ipilimumab. The secondary objective was to further
characterize the clinical benefit of ipilimumab in patients who have progressed on HD IL-2.
We reviewed the records of all patients with metastatic melanoma who received HD IL-2 at …
those previously treated with high-dose interleukin-2 (HD IL-2). The primary objective of this
study was to determine if clinical response or progression-free survival (PFS) to HD IL-2
could predict benefit to subsequent ipilimumab. The secondary objective was to further
characterize the clinical benefit of ipilimumab in patients who have progressed on HD IL-2.
We reviewed the records of all patients with metastatic melanoma who received HD IL-2 at …